De Jong FA - Search Results

1

Irinotecan-induced central nervous system toxicity. Report on two cases and review of the literature.

Hamberg P, De Jong FA, Brandsma D, Verweij J, Sleijfer S. Hamberg P, et al. Among authors: de jong fa. Acta Oncol. 2008;47(5):974-8. doi: 10.1080/02841860701666089. Acta Oncol. 2008. PMID: 17924208 Review. No abstract available.

2

Limited potential of hepatic arterial infusion of irinotecan.

De Jong FA, Mathijssen RH, Verweij J. De Jong FA, et al. J Chemother. 2004 Nov;16 Suppl 5:48-50. doi: 10.1080/1120009x.2004.11782384. J Chemother. 2004. PMID: 15675478

3

Role of pharmacogenetics in irinotecan therapy.

de Jong FA, de Jonge MJ, Verweij J, Mathijssen RH. de Jong FA, et al. Among authors: de jonge mj. Cancer Lett. 2006 Mar 8;234(1):90-106. doi: 10.1016/j.canlet.2005.04.040. Epub 2005 Dec 15. Cancer Lett. 2006. PMID: 16343744 Review.

4

Effects of mannose-binding lectin polymorphisms on irinotecan-induced febrile neutropenia.

van der Bol JM, de Jong FA, van Schaik RH, Sparreboom A, van Fessem MA, van de Geijn FE, van Daele PL, Verweij J, Sleijfer S, Mathijssen RH. van der Bol JM, et al. Among authors: de jong fa. Oncologist. 2010;15(10):1063-72. doi: 10.1634/theoncologist.2010-0033. Epub 2010 Oct 7. Oncologist. 2010. PMID: 20930093 Free PMC article.

5

Hepatic transport, metabolism and biliary excretion of irinotecan in a cancer patient with an external bile drain.

de Jong FA, Kitzen JJ, de Bruijn P, Verweij J, Loos WJ. de Jong FA, et al. Among authors: de bruijn p. Cancer Biol Ther. 2006 Sep;5(9):1105-10. doi: 10.4161/cbt.5.9.3294. Epub 2006 Sep 19. Cancer Biol Ther. 2006. PMID: 16969123

6

Flat-fixed dosing of irinotecan: influence on pharmacokinetic and pharmacodynamic variability.

de Jong FA, Mathijssen RH, Xie R, Verweij J, Sparreboom A. de Jong FA, et al. Clin Cancer Res. 2004 Jun 15;10(12 Pt 1):4068-71. doi: 10.1158/1078-0432.CCR-03-0591. Clin Cancer Res. 2004. PMID: 15217940

7

Effects of methimazole on the elimination of irinotecan.

van der Bol JM, Visser TJ, Loos WJ, de Jong FA, Wiemer EA, van Aken MO, Planting AS, Schellens JH, Verweij J, Mathijssen RH. van der Bol JM, et al. Among authors: de jong fa. Cancer Chemother Pharmacol. 2011 Jan;67(1):231-6. doi: 10.1007/s00280-010-1414-x. Epub 2010 Aug 1. Cancer Chemother Pharmacol. 2011. PMID: 20680278 Free PMC article.

8

Renal function as a predictor of irinotecan-induced neutropenia.

de Jong FA, van der Bol JM, Mathijssen RH, van Gelder T, Wiemer EA, Sparreboom A, Verweij J. de Jong FA, et al. Clin Pharmacol Ther. 2008 Aug;84(2):254-62. doi: 10.1038/sj.clpt.6100513. Epub 2008 Feb 20. Clin Pharmacol Ther. 2008. PMID: 18288083

9

Determination of irinotecan (CPT-11) and SN-38 in human whole blood and red blood cells by liquid chromatography with fluorescence detection.

de Jong FA, Mathijssen RH, de Bruijn P, Loos WJ, Verweij J, Sparreboom A. de Jong FA, et al. Among authors: de bruijn p. J Chromatogr B Analyt Technol Biomed Life Sci. 2003 Oct 5;795(2):383-8. doi: 10.1016/s1570-0232(03)00574-9. J Chromatogr B Analyt Technol Biomed Life Sci. 2003. PMID: 14522044

10

Role of imatinib mesylate (Gleevec/Glivec) in gastrointestinal stromal tumors.

de Jong FA, Verweij J. de Jong FA, et al. Expert Rev Anticancer Ther. 2003 Dec;3(6):757-66. doi: 10.1586/14737140.3.6.757. Expert Rev Anticancer Ther. 2003. PMID: 14686698 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

60 results

Search Page

Filters